Aptevo Therapeutics Inc. (NASDAQ:APVO) VP Randy Joe Maddux acquired 25,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $2.76 per share, for a total transaction of $69,000.00. Following the completion of the transaction, the vice president now directly owns 25,000 shares in the company, valued at $69,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Aptevo Therapeutics Inc. (NASDAQ APVO) traded up $0.46 during midday trading on Friday, reaching $4.23. 985,635 shares of the company’s stock were exchanged, compared to its average volume of 342,962. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76. Aptevo Therapeutics Inc. has a one year low of $1.15 and a one year high of $4.50.

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of Aptevo Therapeutics by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares in the last quarter. Spark Investment Management LLC grew its stake in shares of Aptevo Therapeutics by 167.4% in the 2nd quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock worth $127,000 after buying an additional 38,500 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Aptevo Therapeutics by 11,751.3% in the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after buying an additional 390,379 shares in the last quarter. Finally, Precept Management LLC purchased a new position in shares of Aptevo Therapeutics in the 2nd quarter worth $1,210,000. 32.22% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have issued reports on APVO. ValuEngine downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a report on Thursday, October 5th.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/08/aptevo-therapeutics-inc-apvo-vp-randy-joe-maddux-acquires-25000-shares.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.